Fundación CANNA: how good is this Spanish science blog?

The foundation positions itself as a bridge between academic research and the general public on cannabis use, including medical and recreational use, a wider scope than the wellbeing CBD sold in French shops. It publishes explanatory articles, thematic dossiers and content aimed at an international audience, in several languages, with a scientific advisory committee bringing together researchers specialising in cannabis pharmacology.

The content covers the biology of the plant, cannabinoids, therapeutic uses studied in the international literature, and cultivation practices. This positioning differs from the commercial blog of a CBD shop: the angle is more documentary than promotional. That said, this content is addressed to an international readership and is not written with the French regulatory framework in mind.

Spain has developed an approach to cannabis distinct from that of France, notably with "cannabis social clubs" tolerated under certain conditions and a research framework more open to medical cannabis. Wellbeing CBD sold in France, for its part, falls under a specific framework: a THC threshold of 0.30 % in the finished product, the Novel Food regulation for ingested products since 15 May 2026, and the absence of any health claim validated by the EFSA. Our article on CBD regulation in France in 2026 sets out that framework in detail.

Scientific content published from Spain may deal with valid international research data, but it says nothing about the legal status of a product in France. A study mentioned on a Spanish blog, however serious, never constitutes an authorisation for a health claim on a CBD product sold in France: on that ground only the EFSA, at European level, or the DGCCRF, for advertising control, carry authority.

Consulting international sources broadens your understanding of the subject, but the legal framework applicable to a purchase always remains that of the country of residence and of sale. For a French consumer, the priority markers remain the certificate of analysis of the product bought, compliance with the THC threshold, and the absence of any therapeutic claim on the label, whatever the level of scientific research discussed elsewhere in Europe.

CBD is not a medicine. If in doubt about a product or a claim, check the French regulatory framework in force.

Is Fundación CANNA a recognised authority in France?

No. It is a Spanish research and public education organisation. It has no regulatory power over CBD products sold in France, that competence resting with the EFSA and the DGCCRF.

Do the studies cited on this kind of blog apply to CBD sold in France?

Not directly where health claims are concerned. An international scientific study does not amount to an authorisation for a claim in France: only EFSA validation would allow that, and none exists to date for CBD.

Why do Spain and France have different frameworks on cannabis?

Each member state retains a margin of appreciation on cannabis use, within the limits set by European law on the free movement of goods, notably the CJEU's Kanavape case law.

Should foreign blogs be relied on to choose a CBD product?

They can inform you about general research, but the choice of a product must always rest on its certificate of analysis and its compliance with the French legal framework.